Analytical Overview: Terns Pharmaceuticals Inc (TERN)’s Ratios Tell a Financial Story

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

As of close of business last night, Terns Pharmaceuticals Inc’s stock clocked out at $5.56, down -5.12% from its previous closing price of $5.86. In other words, the price has decreased by -$5.12 from its previous closing price. On the day, 0.57 million shares were traded. TERN stock price reached its highest trading level at $5.98 during the session, while it also had its lowest trading level at $5.47.

Ratios:

To gain a deeper understanding of TERN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.39 and its Current Ratio is at 22.39. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on June 22, 2023, initiated with a Buy rating and assigned the stock a target price of $16.

On June 07, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $18.

On May 31, 2023, ROTH MKM started tracking the stock assigning a Buy rating and target price of $23.ROTH MKM initiated its Buy rating on May 31, 2023, with a $23 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 03 ’24 when Vivo Opportunity, LLC sold 138,066 shares for $6.20 per share. The transaction valued at 856,009 led to the insider holds 268,573 shares of the business.

Vivo Opportunity, LLC sold 101,480 shares of TERN for $674,842 on Apr 02 ’24. The 10% Owner now owns 272,722 shares after completing the transaction at $6.65 per share. On Apr 01 ’24, another insider, Vivo Opportunity, LLC, who serves as the 10% Owner of the company, sold 181,117 shares for $6.99 each. As a result, the insider received 1,266,008 and left with 275,772 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TERN now has a Market Capitalization of 359591872 and an Enterprise Value of 96626416.

Stock Price History:

The Beta on a monthly basis for TERN is -0.45, which has changed by -0.53159225 over the last 52 weeks, in comparison to a change of 0.26265144 over the same period for the S&P500. Over the past 52 weeks, TERN has reached a high of $13.25, while it has fallen to a 52-week low of $3.26. The 50-Day Moving Average of the stock is -7.34%, while the 200-Day Moving Average is calculated to be -3.88%.

Shares Statistics:

It appears that TERN traded 952.62K shares on average per day over the past three months and 832380 shares per day over the past ten days. A total of 64.58M shares are outstanding, with a floating share count of 41.14M. Insiders hold about 36.39% of the company’s shares, while institutions hold 77.42% stake in the company. Shares short for TERN as of 1714435200 were 4487021 with a Short Ratio of 4.71, compared to 1711584000 on 4492887. Therefore, it implies a Short% of Shares Outstanding of 4487021 and a Short% of Float of 7.870000000000001.

Earnings Estimates

Terns Pharmaceuticals Inc (TERN) is presently subject to a detailed evaluation by 8.0 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.29 and a low estimate of -$0.41, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.3 and low estimates of -$0.43.

Analysts are recommending an EPS of between -$1.17 and -$1.63 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$1.42, with 9.0 analysts recommending between -$0.92 and -$1.9.

Most Popular

[the_ad id="945"]